China

The government is expected to account for the majority of the spending.

The group's stake in Ali Health will rise to 59.5% from 56.6% as a result.

Unified healthcare information system provider is quick to respond to help clinicians in China and multiple other countries screen and support patients with 2019-nCov.

A bulk of drug intermediates are sourced from China.

The company launched a video consultation service that connects users to Thai MDs.

It entered a share subscription agreement for $17.9m.

27 contract renewal drugs received a 26.5% average price cut.

Medical content can be viewed in the form of articles, animation, and videos.

The Wuxi Xinwu District Court held that a 2015 land transfer between Wuxi Yilin and Wuxi New District Phoenix Hospital was legal.

It will also boost the headcount in its Shanghai R&D centre to 1,000.

Blame the two-invoice system.

The entrance of Indian players may cut prices further by 30%.

The effects of regulatory change on the sales of patented medicine are expected to be mild.

China-based Weimai’s $155m funding round was one of the quarter’s notable deals.

The number of deals fell to 62 transactions in the same period.

Over the next decade, an estimated $2t investment into Universal Health Coverage (UHC) schemes is expected to land in Asia. The developing markets in the region have traditionally under-funded healthcare at a rate of about 5% of GDP (compared to the average of 12% in OECD countries like Australia and Japan). Whilst some emerging markets in Asia continue to grapple with lingering infection control, all are shifting focus to the more advanced lifestyle diseases.